Three of the first 10 patients with thymoma evaluated by RECIST have partial responses. Findings exceed protocol requirement of two responses among first 16 patients evaluated to proceed with stage 2 of efficacy assessment. Recent immuno-profiling findings continue to be consistent with anti-c
Promontory Therapeutics Inc. , a clinical stage pharmaceutical company advancing immunogenic small molecule approaches in oncology, will present immuno-profiling data from two Phase 2 studies of PT-112 monotherapy at the American Association for Cancer Research (AACR) Annual Meeting, which will be
Agreement broadly reached on PT-112 Recommended Phase 3 Dose (RP3D), patient population, study comparator and key study endpoints Interim analysis allows potential for drug approval prior to study completion Preliminary PT-112 Phase 2 clinical outcomes in metastatic castration-resistant prosta
Thriving on an open and transparent operating style, Phosplatin is led by highly experienced industry experts and a world-renowned Scientific Advisory Board.
Promontory Therapeutics is developing novel small molecule immunogenic anti-cancer agents. Their lead agent, PT-112, is a highly potent immunogenic cell death (ICD) inducer, currently in Phase 2 clinical development.
